{"id":34214,"date":"2026-03-18T06:34:15","date_gmt":"2026-03-18T06:34:15","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/34214\/"},"modified":"2026-03-18T06:34:15","modified_gmt":"2026-03-18T06:34:15","slug":"mankind-pharma-shares-gain-3-on-acquiring-rivotril-brand-from-roche-for-indian-market","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/34214\/","title":{"rendered":"Mankind Pharma shares gain 3% on acquiring Rivotril brand from Roche for Indian market"},"content":{"rendered":"<p>Shares of <a class=\"stockpage_articles\" href=\"https:\/\/www.cnbctv18.com\/market\/stocks\/mankind-pharma-ltd-share-price\/MP22\/\" target=\"_blank\" rel=\"noopener nofollow\">Mankind Pharma Ltd<\/a> surged nearly 3% on Wednesday, March 18, after it announced the acquisition of the Rivotril brand for the Indian market from Roche.<\/p>\n<p>In a press release filed with the exchanges, the company said it has secured exclusive rights to manufacture, market and distribute Rivotril in India, in a move that will strengthen its presence in the chronic and central nervous system (CNS) therapies segment.<\/p>\n<p>\nRivotril is an innovator formulation of clonazepam and is widely prescribed for neurological and psychiatric conditions.<br \/>Mankind Pharma said the acquisition adds a well-established brand with a strong clinical legacy and specialist recall to its portfolio, complementing its existing neuro\/CNS offerings.&#13;<br \/>\nAtish Majumdar, Senior President, Sales &amp; Marketing, Mankind Pharma Specialty Business, said, &#8220;This acquisition is aligned with our strategic focus on strengthening our presence in chronic therapies and speciality therapies.&#8221;<\/p>\n<p>Citing strong opportunities through the platform, he said, &#8220;Leveraging our large field force and nationwide distribution network, we are well-positioned to build the brand and support physicians in delivering better outcomes for patients across India.\u201d<\/p>\n<p>Mankind Pharma added that the deal also creates opportunities for future line extensions in the CNS segment, helping address evolving patient and physician needs.<\/p>\n<p>Mankind Pharma currently engages with over five lakh doctors and has a strong presence across both urban and semi-urban markets, supporting deeper penetration of its speciality portfolio.<\/p>\n<p>For the December quarter, the company posted a<a href=\"https:\/\/www.cnbctv18.com\/market\/earnings\/mankind-pharma-q3-profit-rises-7-5-yoy-to-rs-408-7-crore-margins-improve-ws-l-19841073.htm\" rel=\"nofollow noopener\" target=\"_blank\"> 7.5% year-on-year growth in net profit to \u20b9408.7 crore<\/a> from \u20b9380.2 crore in Q3FY25.\u00a0Revenue rose 11.5% YoY to \u20b93,567 crore from \u20b93,198 crore last year. EBITDA increased 12.7% to \u20b9919.6 crore from \u20b9816.2 crore, and EBITDA margin stood at 25.8%, compared with 25.5% in the same quarter last year.<br \/>&#13;\n<\/p>\n<p>Following the announcement, shares of the company gained nearly 2.75% to \u20b92,125.10. The stock has declined 19.60% in the last six months.<\/p>\n","protected":false},"excerpt":{"rendered":"Shares of Mankind Pharma Ltd surged nearly 3% on Wednesday, March 18, after it announced the acquisition of&hellip;\n","protected":false},"author":2,"featured_media":34215,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[20307,20306,20302,20309,20305,20303,20308,20304,134],"class_list":{"0":"post-34214","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-chronic-therapies","9":"tag-cns-therapies","10":"tag-mankind-pharma","11":"tag-mankind-pharma-market","12":"tag-mankind-pharma-rivotril","13":"tag-mankind-pharma-shares","14":"tag-mankind-pharma-stock","15":"tag-rivotril-acquisition","16":"tag-roche"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116248789811155810","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/34214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=34214"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/34214\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/34215"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=34214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=34214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=34214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}